"GTP Phosphohydrolases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that hydrolyze GTP to GDP. EC 3.6.1.-.
| Descriptor ID |
D020558
|
| MeSH Number(s) |
D08.811.277.040.330
|
| Concept/Terms |
GTP Phosphohydrolases- GTP Phosphohydrolases
- Phosphohydrolases, GTP
- GTPase
- GTPases
- Guanosinetriphosphatases
- Guanosine Triphosphate Phosphohydrolases
- Phosphohydrolases, Guanosine Triphosphate
- Triphosphate Phosphohydrolases, Guanosine
- GTP Phosphohydrolase
- Phosphohydrolase, GTP
|
Below are MeSH descriptors whose meaning is more general than "GTP Phosphohydrolases".
Below are MeSH descriptors whose meaning is more specific than "GTP Phosphohydrolases".
This graph shows the total number of publications written about "GTP Phosphohydrolases" by people in this website by year, and whether "GTP Phosphohydrolases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 4 | 1 | 5 |
| 1996 | 2 | 0 | 2 |
| 1997 | 4 | 0 | 4 |
| 1998 | 4 | 4 | 8 |
| 1999 | 4 | 2 | 6 |
| 2000 | 5 | 1 | 6 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 5 | 5 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 9 | 5 | 14 |
| 2014 | 6 | 6 | 12 |
| 2015 | 3 | 9 | 12 |
| 2016 | 6 | 4 | 10 |
| 2017 | 6 | 4 | 10 |
| 2018 | 4 | 3 | 7 |
| 2019 | 7 | 5 | 12 |
| 2020 | 1 | 3 | 4 |
| 2021 | 5 | 1 | 6 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "GTP Phosphohydrolases" by people in Profiles.
-
A human mitofusin 2 mutation can cause mitophagic cardiomyopathy. Elife. 2023 11 01; 12.
-
Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors. Sci Immunol. 2023 09 29; 8(87):eabq2424.
-
Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature. 2023 Jul; 619(7970):616-623.
-
MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR. Cancer Commun (Lond). 2023 07; 43(7):808-833.
-
Leukocytosis and Splenomegaly in a Neonate With NRAS Mutation. Clin Pediatr (Phila). 2024 May; 63(4):451-455.
-
RbgA ensures the correct timing in the maturation of the 50S subunits functional sites. Nucleic Acids Res. 2022 10 28; 50(19):10801-10816.
-
Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022 07 15; 28(14):3002-3010.
-
Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. J Exp Clin Cancer Res. 2022 Mar 12; 41(1):95.
-
Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D. Comput Biol Med. 2021 12; 139:104946.